Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Henry Schein, Inc.    HSIC   US8064071025

HENRY SCHEIN, INC.

 (HSIC)

3
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Henry Schein, Inc. : Henry Schein Reports Record First Quarter Results

05/08/2012| 07:05am US/Eastern
Recommend:
0

MELVILLE, N.Y., May 8, 2012 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of healthcare products and services to office-based dental, medical and animal health practitioners, today reported record financial results for the quarter ended March 31, 2012.

Net sales for the first quarter of 2012 were $2.1 billion, an increase of 7.8% compared with the first quarter of 2011. This consists of 8.4% growth in local currencies and a 0.6% decline related to foreign currency exchange. In local currencies, internally generated sales increased 7.8% and acquisition growth was 0.6% (see Exhibit A for details of sales growth).

Net income attributable to Henry Schein, Inc. for the first quarter of 2012 was $80.8 million or $0.89 per diluted share. Excluding restructuring costs of $11.8 million pre-tax or $0.09 per diluted share, net income attributable to Henry Schein, Inc. for the first quarter of 2012 was $89.1 million or $0.98 per diluted share, an increase of 16.4% and 19.5%, respectively, compared with the first quarter of 2011.

"This is the first quarter we are reporting net sales results for our global customer-centric business units, and we are pleased with growth in local currencies of mid-single-digits or better for each unit," commented Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "Early in 2012 we implemented and largely completed a restructuring with the goal of optimizing our cost structure and improving profitability. Based on the strength of our first quarter financial results and our continued confidence in our outlook for the rest of the year, we are increasing our EPS guidance range for 2012. We look forward to the future with a more efficient organization and an ever-sharper global view of customers and their evolving needs."

Global Dental sales of $1.2 billion increased 5.5%, consisting of 6.6% growth in local currencies and a 1.1% decline related to foreign currency exchange. In local currencies, internally generated sales increased 6.2% and acquisition growth was 0.4%. The 6.2% internal growth in local currencies included 4.5% growth in North America and 8.9% International growth.

"Dental sales growth was strong due to stable or improved patient traffic to dental offices in the major markets we serve. We believe that we continued to gain market share in our global dental business," commented Mr. Bergman.

Global Animal Health sales of $525.6 million increased 15.3%, including 15.4% growth in local currencies and a 0.1% decline related to foreign currency exchange. In local currencies, internally generated sales increased 14.8% and acquisition growth was 0.6%. The 14.8% internal growth in local currencies included 15.8% growth in North America and 13.7% International growth.

"On a global basis our Animal Health business continued to make impressive gains in market share, in large part due to the expanding breadth and depth of our product offerings and strengthening relationships with our customers," commented Mr. Bergman. "We recently announced the signing of a definitive agreement to acquire AUV Veterinary Services, the leading distributor serving animal health practitioners in the Netherlands and Belgium. By expanding our European animal health footprint, we have an opportunity to provide even greater value to our customers and manufacturing partners."

Global Medical sales of $354.8 million increased 4.0%, including 4.2% growth in local currencies and a 0.2% decline related to foreign currency exchange. In local currencies, internally generated sales increased 3.6% and acquisition growth was 0.6%. The 3.6% internal growth in local currencies included 3.4% growth in North America and 7.4% International growth.

"Our North America Medical business comprises well over 90% of our global Medical sales. Growth in that market was largely fueled by increased penetration of larger group practices and solid growth in sales of pharmaceutical products. These improvements were somewhat offset by lower sales of diagnostic consumable products due to a generally mild winter," remarked Mr. Bergman.

Global Technology and Value-Added Services sales of $62.9 million increased 13.1%, including 13.2% growth in local currencies and a 0.1% decline related to foreign currency exchange. In local currencies, internally generated sales increased 9.0% and acquisition growth was 4.2%. The 9.0% internal growth in local currencies included 9.9% growth in North America and 4.0% International growth.

"The performance of our Technology and Value-Added Services group continued to be excellent, with strong internal sales growth in the U.S. bolstered by strategic acquisitions. More than 85% of revenue from our Technology and Value-Added Services group is derived from North America," explained Mr. Bergman. "First quarter results included particular strength in our electronic services business."

Stock Repurchase Plan

The Company announced that it repurchased approximately 540,000 shares of its common stock during the first quarter at an average price of $70.92 per share, or approximately $39.0 million. The impact of the repurchase of shares on first quarter diluted EPS was not material. At the close of the first quarter, Henry Schein had $61.4 million authorized for future repurchases of its common stock.

Subsequent to the close of the first quarter, the Company's Board of Directors authorized the repurchase of up to an additional $200 million of shares of the Company's common stock.

2012 EPS Guidance

Henry Schein today raised 2012 financial guidance, as follows:

    --  For 2012 the Company expects diluted EPS attributable to Henry Schein,
        Inc. to be $4.30 to $4.40, which represents growth of 8% to 11% compared
        with 2011 results.  This compares with previous guidance for diluted EPS
        to be $4.25 to $4.34.
    --  The Company notes that the 2012 fiscal year includes one less week than
        2011.
    --  Guidance for 2012 diluted EPS attributable to Henry Schein, Inc.
        excludes restructuring costs.
    --  The Company estimates restructuring costs for Q2 2012 will be
        approximately $2-$4 million on a pre-tax basis, or $0.02 to $0.03 per
        diluted share.
    --  Guidance for 2012 diluted EPS attributable to Henry Schein, Inc. is for
        current continuing operations as well as completed or previously
        announced acquisitions, and does not include the impact of potential
        future acquisitions, if any.

First Quarter Conference Call Webcast

The Company will hold a conference call to discuss first quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein, Inc.

Henry Schein, Inc. (NASDAQ: HSIC) is the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs nearly 15,000 Team Schein Members and serves approximately 775,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. The Company's sales reached a record $8.5 billion in 2011, and have grown at a compound annual rate of 18% since Henry Schein became a public company in 1995. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; possible increases in the cost of shipping our products or other service issues with our third-party shippers; general global macro-economic conditions; disruptions in financial markets; possible volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our international operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from rapid technological change; risks from disruption to our information systems; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

(TABLES TO FOLLOW)

                                                  HENRY SCHEIN, INC.
                                          CONSOLIDATED STATEMENTS OF INCOME
                                        (in thousands, except per share data)
                                                     (unaudited)

                               Three Months Ended
                               ------------------
                                   March 31,                                    March 26,
                                             2012                                    2011
                                             ----                                    ----


    Net sales                                                       $2,099,019            $1,947,761
    Cost of sales                                                    1,488,440             1,381,939
                                                                     ---------             ---------
           Gross profit                                                610,579               565,822
    Operating expenses:
        Selling, general
         and administrative                                            465,452               441,522
        Restructuring costs                                             11,832                     -
                                                                        ------                   ---
           Operating income                                            133,295               124,300
    Other income
     (expense):
        Interest income                                                  3,330                 3,933
        Interest expense                                                (7,640)               (8,085)
        Other, net                                                         525                   323
                                                                           ---                   ---
           Income before taxes
            and equity in
            earnings of
            affiliates                                                 129,510               120,471
    Income taxes                                                       (41,840)              (39,153)
    Equity in earnings
     of affiliates                                                       1,391                 1,653
                                                                         -----                 -----
    Net income                                                          89,061                82,971
        Less: Net income
         attributable to
         noncontrolling
          interests                                                     (8,309)               (6,476)
                                                                        ------                ------
    Net income
     attributable to
     Henry Schein, Inc.                                                $80,752               $76,495
                                                                       =======               =======

    Earnings per share
     attributable to
      Henry Schein, Inc.:

        Basic                                                            $0.92                 $0.84
                                                                         =====                 =====
        Diluted                                                          $0.89                 $0.82
                                                                         =====                 =====

    Weighted-average
     common shares
     outstanding:
        Basic                                                           88,216                90,615
                                                                        ======                ======
        Diluted                                                         90,666                93,161
                                                                        ======                ======

                                                            HENRY SCHEIN, INC.
                                                        CONSOLIDATED BALANCE SHEETS
                                              (in thousands, except share and per share data)

                                                    March 31,                                 December 31,
                                                          2012                                        2011
                                                          ----                                        ----
                                                   (unaudited)
    ASSETS
    Current assets:
        Cash and cash equivalents                                                 $101,813                   $147,284
        Accounts receivable, net of
         reserves of $62,145 and $65,853                                           957,470                    888,248
        Inventories, net                                                           975,797                    947,849
        Deferred income taxes                                                       54,553                     54,970
        Prepaid expenses and other                                                 217,377                    234,157
                                                                                   -------                    -------
                Total current assets                                             2,307,010                  2,272,508
    Property and equipment, net                                                    259,760                    262,088
    Goodwill                                                                     1,483,094                  1,497,108
    Other intangibles, net                                                         409,142                    409,612
    Investments and other                                                          300,627                    298,828
                                                                                   -------                    -------
                Total assets                                                    $4,759,633                 $4,740,144
                                                                                ==========                 ==========

    LIABILITIES AND STOCKHOLDERS'
     EQUITY
    Current liabilities:
        Accounts payable                                                          $571,341                   $621,468
        Bank credit lines                                                            5,004                     55,014
        Current maturities of long-term
         debt                                                                       23,028                     22,819
        Accrued expenses:
           Payroll and related                                                     147,662                    191,173
           Taxes                                                                   131,811                    121,234
           Other                                                                   260,290                    259,932
                                                                                   -------                    -------
                Total current liabilities                                        1,139,136                  1,271,640
    Long-term debt                                                                 453,058                    363,524
    Deferred income taxes                                                          186,844                    188,739
    Other liabilities                                                               84,081                     80,568
                                                                                    ------                     ------
                Total liabilities                                                1,863,119                  1,904,471

    Redeemable noncontrolling
     interests                                                                     369,039                    402,050
    Commitments and contingencies

    Stockholders' equity:
       Preferred stock, $.01 par value,
        1,000,000 shares authorized,
           none outstanding                                                              -                          -
       Common stock, $.01 par value,
        240,000,000 shares authorized,
           90,179,606 outstanding on March
            31, 2012 and
           89,928,082 outstanding on
            December 31, 2011                                                          902                        899
       Additional paid-in capital                                                  410,140                    401,262
       Retained earnings                                                         2,061,263                  2,007,477
       Accumulated other comprehensive
        income                                                                      53,744                     22,584
                                                                                    ------                     ------
       Total Henry Schein, Inc.
        stockholders' equity                                                     2,526,049                  2,432,222
       Noncontrolling interests                                                      1,426                      1,401
                Total stockholders' equity                                       2,527,475                  2,433,623
                                                                                 ---------                  ---------
                Total liabilities, redeemable
                 noncontrolling interests and
                 stockholders' equity                                           $4,759,633                 $4,740,144
                                                                                ==========                 ==========

                                                            HENRY SCHEIN, INC.
                                                   CONSOLIDATED STATEMENTS OF CASH FLOWS
                                                              (in thousands)
                                                                (unaudited)

                                            Three Months Ended
                                            ------------------
                                                March 31,                                   March 26,
                                                          2012                                   2011
                                                          ----                                   ----

    Cash flows from
     operating
     activities:
        Net income                                                                 $89,061             $82,971
        Adjustments to
         reconcile net
         income to net cash
           provided by (used
            in) operating
            activities:
                Depreciation and
                 amortization                                                       30,420              28,348
                Stock-based
                 compensation
                 expense                                                             8,754               8,345
                Provision for losses
                 on trade and other
                     accounts receivable                                             1,144               1,728
                Benefit from
                 deferred income
                 taxes                                                              (8,182)             (6,772)
                Equity in earnings
                 of affiliates                                                      (1,391)             (1,653)
                Distributions from
                 equity affiliates                                                   3,324                 449
                Other                                                                2,901               2,281
                Changes in operating
                 assets and
                 liabilities,
                     net of acquisitions:
                       Accounts receivable                                         (57,433)             10,990
                       Inventories                                                 (12,532)             (6,944)
                       Other current assets                                         12,404              (1,131)
                       Accounts payable and
                        accrued expenses                                          (117,075)            (70,138)
    Net cash provided by
     (used in) operating
     activities                                                                    (48,605)             48,474
                                                                                   -------              ------

    Cash flows from
     investing
     activities:
        Purchases of fixed
         assets                                                                    (12,223)            (10,458)
        Payments for equity
         investments and
         business
            acquisitions, net of
             cash acquired                                                         (18,980)           (133,614)
        Proceeds from sales
         of available-for-
         sale securities                                                             1,150               2,100
        Other                                                                       (2,051)                413
    Net cash used in
     investing
     activities                                                                    (32,104)           (141,559)
                                                                                   -------            --------

    Cash flows from
     financing
     activities:
        Proceeds from
         (repayments of)
         bank borrowings                                                           (50,016)             55,660
        Proceeds from
         issuance of long-
         term debt                                                                 100,000               3,000
        Principal payments
         for long-term debt                                                        (10,650)             (1,526)
        Proceeds from
         issuance of stock
         upon exercise
            of stock options                                                        30,039              18,814
        Payments for
         repurchases of
         common stock                                                              (38,565)            (27,098)
        Excess tax benefits
         related to stock-
         based
            compensation                                                             8,548               5,797
        Distributions to
         noncontrolling
         shareholders                                                               (2,081)             (1,062)
        Acquisition of
         noncontrolling
         interests in
            subsidiaries                                                            (6,366)               (366)
        Other                                                                            -                 (90)
    Net cash provided by
     financing
     activities                                                                     30,909              53,129
                                                                                    ------              ------


    Net change in cash
     and cash
     equivalents                                                                   (49,800)            (39,956)
    Effect of exchange
     rate changes on
     cash and
        cash equivalents                                                             4,329               6,320
    Cash and cash
     equivalents,
     beginning of period                                                           147,284             150,348
    Cash and cash
     equivalents, end of
     period                                                                       $101,813            $116,712
                                                                                  ========            ========

Note: Certain prior period amounts have been reclassified to conform to the current presentation.

    Exhibit A

                                                      Henry Schein, Inc.
                                                      2012 First Quarter
                                                   Sales Growth Rate Summary
                                                          (unaudited)

                                                     Q1 2012 over Q1 2011
                                                     --------------------

    Global                      Consolidated                 Dental          Animal         Medical       Technology /
                                                                             Health                           VAS
    ---                                                                      ------                           ---

    Local Internal Sales Growth               7.8%                     6.2%         14.8%            3.6%               9.0%

    Acquisitions                              0.6%                     0.4%          0.6%            0.6%               4.2%
                                              ---                      ---           ---             ---                ---

    Local Currency Sales Growth               8.4%                     6.6%         15.4%            4.2%              13.2%

    Foreign Currency Exchange                -0.6%                    -1.1%         -0.1%           -0.2%              -0.1%
                                             ----                     ----          ----            ----               ----

         Total Sales Growth                   7.8%                     5.5%         15.3%            4.0%              13.1%
                                              ===                      ===          ====             ===               ====

                                                                                                          Technology /
                                                                                                              VAS
                                                                                                              ---
    North America               Consolidated                 Dental          Animal         Medical
                                                                             Health
    ---                                                                      ------

    Local Internal Sales Growth               6.5%                     4.5%         15.8%            3.4%               9.9%

    Acquisitions                              0.5%                     0.3%          0.0%            0.6%               4.9%
                                              ---                      ---           ---             ---                ---
                                                                                          .
    Local Currency Sales Growth               7.0%                     4.8%         15.8%            4.0%              14.8%

    Foreign Currency Exchange                -0.1%                    -0.2%          0.0%            0.0%              -0.1%
                                             ----                     ----           ---             ---               ----

         Total Sales Growth                   6.9%                     4.6%         15.8%            4.0%              14.7%
                                              ===                      ===          ====             ===               ====

                                                                                                          Technology /
                                                                                                              VAS
                                                                                                              ---
    International               Consolidated                 Dental          Animal         Medical
                                                                             Health
    ---                                                                      ------

    Local Internal Sales Growth              10.4%                     8.9%         13.7%            7.4%               4.0%

    Acquisitions                              0.7%                     0.6%          1.2%            0.0%               0.0%
                                              ---                      ---           ---             ---                ---

    Local Currency Sales Growth              11.1%                     9.5%         14.9%            7.4%               4.0%

    Foreign Currency Exchange                -1.7%                    -2.6%          0.0%           -3.5%              -0.3%
                                             ----                     ----           ---            ----               ----

         Total Sales Growth                   9.4%                     6.9%         14.9%            3.9%               3.7%
                                              ===                      ===          ====             ===                ===

     Exhibit B

                                                                     Henry Schein, Inc.
                                                                     2012 First Quarter
                                     Reconciliation of GAAP results of net income attributable to Henry Schein, Inc. to
                                              non-GAAP results of net income attributable to Henry Schein, Inc.
                                                            (in thousands, except per share data)
                                                                         (unaudited)

                                                                                                                        First Quarter and YTD
                                                                                                                                            2012          2011%
                                                                                                                                                                Growth
     From Net Income Attributable to Henry Schein, Inc.
     --------------------------------------------------
     Net Income Attributable to Henry Schein, Inc.                                                                                       $80,752       $76,495          5.6%
     Diluted EPS from Net Income attributable to Henry Schein, Inc.                                                                        $0.89         $0.82          8.5%
     --------------------------------------------------------------                                                                        -----         -----          ---

     Non-GAAP Adjustments (after-tax)
     Restructuring costs                                                                                                                  $8,301 $           -
                                                                                                                                          ------ -------------
     Net Income attributable to Henry Schein, Inc.                                                                                        $8,301            $0
     Diluted EPS from Net Income attributable to Henry Schein, Inc.                                                                        $0.09         $0.00

     Adjusted Results From Net Income Attributable to Henry Schein, Inc.
     -------------------------------------------------------------------
     Net Income attributable to Henry Schein, Inc.                                                                                       $89,053       $76,495         16.4%
     Diluted EPS from Net Income attributable to Henry Schein, Inc.                                                                        $0.98         $0.82         19.5%
     --------------------------------------------------------------                                                                        -----         -----         ----

This non-GAAP comparison is being presented in order to provide a more comparable basis for analysis. Earnings per share numbers may not sum due to rounding.

SOURCE Henry Schein, Inc.

Recommend :
0
Partner Area
React to this article
 
Latest news on HENRY SCHEIN, INC.
2d ago HENRY SCHEIN, INC.: Henry Schein Dental And American Dental Hygienists' Associa..
06/11 HENRY SCHEIN, INC.: Masimo Signs Far-Reaching Pulse Oximetry Distribution Deal ..
06/06 HENRY SCHEIN, INC.: Henry Schein Cares Calendar of Caring Community Wellness Pr..
06/05 HENRY SCHEIN, INC.: Align Technology and Henry Schein Extend Benefits of Straig..
05/31 HENRY SCHEIN, INC.: Stanley Bergman Delivers Commencement Address At Stony Broo..
05/29 HENRY SCHEIN, INC.: Henry Schein to Present at Four Conferences in June
05/21 HENRY SCHEIN, INC.: Henry Schein Opens Its Disaster Relief Hotline to Support C..
05/13 HENRY SCHEIN, INC.: Henry Schein To Present At Three Conferences In May
05/07 HENRY SCHEIN, INC.: Henry Schein Reports Record First Quarter Results
05/06 HENRY SCHEIN, INC.: Henry Schein Named As One Of FORTUNE's Largest 300 Corporat..
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.